Effets d'une prise chronique de salbutamol au cours d'un exercice maximal |
| |
| Institution: | 1. LAPSEP, UFR STAPS, université d''Orléans, F. 45062 Orléans cedex 02, France;2. Service de Physiopathologie de l''Exercice, F. 45062 Orléans cedex 02, France;3. LNDD, F. 92290 Chatenay-Malabry, France;1. Division of Clinical Toxicology, Department of Emergency Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia;2. Virginia Poison Center, Richmond, Virginia;3. Division of Pulmonary Disease and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia;4. Toxicology Laboratory, Departments of Pathology and Forensic Science, Virginia Commonwealth University, Richmond, Virginia;1. Department of Internal Medicine (Pulmonology), University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany;2. Department of Lung Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany;3. Department of Biochemistry, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany;4. Department of Sports Medicine, Medical Clinic VII, University Hospital Heidelberg, University of Heidelberg, Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany;5. Department of Medical Pharmacology, Acibadem University, İstanbul, Turkey;6. Department of Pathology, Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany;1. Secteur de pharmacie clinique, service de pharmacie, hôpital de la Timone, Assistance publique–Hôpitaux de Marseille, 264, rue Saint-Pierre, 13005 Marseille, France;2. EA3279, service d’épidémiologie et d’économie de la santé, Aix-Marseille université, 13005 Marseille, France;3. Service de pharmacie clinique, faculté de pharmacie, Aix-Marseille université, 13005 Marseille, France;1. CHU de Rennes, CHU Pontchaillou, laboratoire de toxicologie biologique et médico-légale, 35033 Rennes, France;2. Université Rennes 1, faculté de pharmacie, 35043 Rennes, France;3. CHU de Rennes, pôle pharmacie, 35033 Rennes, France;4. Inserm, UMR991 « Foie, métabolismes et cancer », 35043 Rennes, France;1. Institute of Nuclear Sciences Vinca, University of Belgrade, Laboratory of Radiobiology and Molecular Genetics, Mike Petrovica Alasa 12-14, 11000 Belgrade, Serbia;2. School of Medicine, University of St Andrews, North Haugh, St Andrews KY16 9TF, United Kingdom;3. Institute of Histology and Embryology “Aleksandar Đ. Kostić”, Faculty of Medicine, University of Belgrade, Visegradska 26, 11000 Belgrade, Serbia;4. Institute of Nuclear Sciences Vinca, University of Belgrade, Laboratory of Physical Chemistry, Mike Petrovica Alasa 12-14, 11000 Belgrade, Serbia;5. Dedinje Cardiovascular Institute, Belgrade University, School of Medicine, Heroja Milana Tepica 1, 11000 Belgrade, Serbia |
| |
| Abstract: | IntroductionThe aim of the study is to assess the effects of chronic therapeutical β2-agonist intake on performance during maximal dynamic exercise.SynthesisWe studied, according to a double blind, randomized cross-over protocol, the effects of chronic salbutamol intake during a classic maximal VO2max test in 14 healthy female volunteers. Performance, metabolic and hormonal parameters were monitored in this study. Sal did not modify significantly maximal aerobic power or VO2max. In parallel, no change was found in the metabolic and hormonal parameters investigated.ConclusionOn the contrary to sub- and supramaximal exercise, short-term salbutamol intake did not induce any ergogenic or metabolic effects during a classic maximal exercise. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
